Thinking of joining a study?

Register your interest

Become a volunteer?

NCT03243331 | COMPLETED | Triple Negative Breast Cancer

An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer
Sponsor:

Kathy Miller

Information provided by (Responsible Party):

Kathy Miller

Brief Summary:

Phase 1 study to evaluate the safety and effect of Gedatolisib and PTK7-ADC for the treatment of triple negative breast cancer

Condition or disease

Triple Negative Breast Cancer

Metastatic Breast Cancer

Intervention/treatment

Gedatolisib

PTK7-ADC

Phase

PHASE1

Study Type : INTERVENTIONAL
Estimated Enrollment : 18 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer
Actual Study Start Date : 2018-01-19
Estimated Primary Completion Date : 2020-05-27
Estimated Study Completion Date : 2020-05-27

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Metastatic Triple-negative Breast Cancer
  • * Willingness to undergo tumor biopsy
  • * Patients must have received at least 1 prior chemotherapy regimen for metastatic disease
Exclusion Criteria
  • * Previous treatment with mTOR inhibitor
  • * Untreated brain metastases
An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer

Location Details

NCT03243331

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Not yet recruiting

United States, Indiana

IU Simon Cancer Center

Indianapolis, Indiana, United States, 46202